

## New AbbVie Immunology Assets Target Large Markets

AbbVie Immunology portfolio to offer three strong assets with the potential to be positioned as best-in-class therapies

Immunology market remains attractive with 6% global market CAGR through 2025, driven by increasing bio-penetration across all geographies and indications

AbbVie Immunology to maintain categorical leadership over our Long-Range Plan horizon

	Rheumatology			Dermatology		Gastroenterology	
	RA	PsA	AS	PsO	AD	CD	UC
Targeted Immune Modulator (TIM)							
Estimated 2025 Market Size*	~\$29Bn	~\$10Bn	~\$8Bn	~\$17Bn	~\$7Bn	~\$11Bn	~\$7Bn

Source: AbbVie Investor Presentation